Global Irritable Bowel Syndrome IBS Overview
Irritable bowel syndrome is intestinal disorder that affects large intestine and causes muscle contractions as well as inflammation in the intestine along with abnormalities in the nervous system. Symptoms of irritable bowel syndrome include cramping, abdominal pain, diarrhoea, and bloating constipation. Exact cause of irritable bowel syndrome is unknown but it is associated with the food habits along with stress and family history of IBS. Treatment of IBS focuses on relieving patients from these symptoms. Also some medications available in market are Rifaximine, Lubiprostone, and Eluxadoline.
Increasing prevalence of irritable bowel syndrome across the globe, coupled with rising label extension of existing products are major factors expected to drive growth of the global market in the near future. In addition, increasing uptake of irritable bowel syndrome drugs as well as commercialization of the new products are other factors anticipated to drive growth of the target market over the forecast period.
irritable bowel syndrome treatment market has been segmented on the basis of drug type, medical condition, distribution channel, and region.
The drug type segment includes Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, and others. On the basis of medical condition irritable bowel syndrome treatment market has been segmented as IBS diarrhea and IBS constipation. On the basis of distribution channel irritable bowel syndrome treatment market has been segmented into hospital pharmacies, online pharmacies, and retail pharmacies.
On the basis of region the target market has been segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to hold major market share compared to other region in forecast period.
The market in North America account for major share in the irritable bowel syndrome treatment market owing to well established healthcare infrastructure and high patient awareness in the countries of this region. The market in Asia specific is expected to register fastest growth during the forecast period due to high prevalence rate of irritable bowel syndrome.
Key players operating in the irritable bowel syndrome (IBS) treatment market includes Ironwood Pharmaceuticals, Allergan, Astellas, Takeda, Sucampo, Salix, AstraZeneca, Sebela Pharmaceuticals, Synergy Pharma, and Ardelyx.
Global Irritable Bowel Syndrome IBS Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Preview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Procedure Type
- Market Snippet, By Gender
- Market Snippet, By End User
- Market Snippet, By Region
- Opportunity Map Analysis
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- Impact Analysis
- PEST Analysis
- Porter’s Analysis
- Market Dynamics
- Market Segmentation, By Procedure Type, 2024 – 2034, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2019 — 2029
- Y-o-Y Growth Analysis (%), 2024 – 2034
- Segment Trends
- Assisted Reproductive Technology (ART)
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
-
- In-vitro Fertilization (IVF)
- Surrogacy
-
- Artificial Insemination
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
-
- Intrauterine Insemination
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Intracervical Insemination
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Intratubal Insemination
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Intrauterine Insemination
-
- Fertility Surgeries
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Other Procedures (Egg Freezing, Sperm Freezing, and Embryo Freezing)
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Overview
- Market Segmentation, By Gender, 2024 – 2034, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2019 — 2029
- Y-o-Y Growth Analysis (%), 2024 – 2034
- Segment Trends
- Male
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Female
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Overview
- Market Segmentation, By End User, 2024 – 2034, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2019 — 2029
- Y-o-Y Growth Analysis (%), 2024 – 2034
- Segment Trends
- Fertility Centers
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Hospitals and Clinics
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Research Institutes
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Cryobanks
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Overview
- Global Market, By Region, 2024 – 2034, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2019 — 2029
- Y-o-Y Growth Analysis (%), 2024 – 2034
- Regional Trends
- North America
- Market Size and Forecast (US$ Bn), By Procedure Type, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Gender, 2024 – 2034
- Market Size and Forecast (US$ Bn), By End User, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Bn), By Procedure Type, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Gender, 2024 – 2034
- Market Size and Forecast (US$ Bn), By End User, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Bn), By Procedure Type, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Gender, 2024 – 2034
- Market Size and Forecast (US$ Bn), By End User, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Bn), By Procedure Type, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Gender, 2024 – 2034
- Market Size and Forecast (US$ Bn), By End User, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Bn), By Procedure Type, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Gender, 2024 – 2034
- Market Size and Forecast (US$ Bn), By End User, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Overview
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- The Cooper Companies Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Cook Group Incorporated
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Thermo Fisher Scientific Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Vitrolife AB
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Esco Micro Pte. Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Genea Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- IVFtech ApS
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Irvine Scientific
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- The Baker Company, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- The Cooper Companies Inc.
- Analyst Views
- Section
- Research Methodology
- About Us
- Contact
FAQs
The market report has been segmented on the basis of drug type, medical condition, distribution channel, and region.
Emerging trends include the development of novel therapeutics targeting gut microbiota, the exploration of non-pharmacological interventions, and the emphasis on personalized treatment approaches for IBS. Opportunities arise from the increasing prevalence of IBS, advancements in understanding the underlying mechanisms, and the potential for targeted therapies with improved efficacy and reduced side effects.
Key factors include the rising prevalence of IBS globally, the impact of lifestyle factors on digestive health, advancements in diagnostic methods, and the demand for effective and well-tolerated treatment options. Additionally, increased awareness of IBS among healthcare professionals and patients, as well as the growing focus on patient-centric care, contribute to market growth.
Regions covered include North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America is expected to dominate the market due to a well-established healthcare infrastructure, high prevalence of IBS, and significant investments in research and development. However, the Asia-Pacific region is experiencing notable growth, driven by increasing healthcare awareness, rising incidences of IBS, and the expansion of pharmaceutical markets in countries like China and India.
The prominent player operating in the irritable bowel syndrome treatment market include Ironwood Pharmaceuticals, Allergan plc, Astellas pharma inc., Takeda Pharmaceutical Company Ltd., Mallinckrodt Pharmaceuticals, Salix pharmaceuticals, AstraZeneca plc, Sebela Pharmaceuticals inc., Synergy Pharmaceuticals inc., and Ardelyx inc.